BLT-3

BLT-3 is an inhibitor of scavenger receptor class B type I (SR-BI) that exerts reversible, non-cell-type-specific inhibitory effects on SR-BI-mediated lipid transport. BLT-3 inhibits SR-BI-mediated selective lipid uptake from HDL as well as cholesterol efflux from cells to HDL. BLT-3 enhances the binding of HDL to SR-BI. BLT-3 is applicable to research related to atherosclerosis and coronary heart disease^[1]. In Vitro:BLT-3 inhibits SR-BI-mediated DiI uptake from DiI-HDL in ldlA[mSR-BI] cells, with an IC₅₀ of 0.51 μM^[1].
BLT-3 inhibits SR-BI-mediated [³H]CE uptake from [³H]CE-HDL in ldlA[mSR-BI] cells, with an IC₅₀ of 2.3 μM^[1].
BLT-3 inhibits SR-BI-mediated [³H]CE uptake from [³H]CE-HDL in Y1-BS1 cells, with an IC₅₀ of 1.7 μM^[1].
BLT-3 inhibits SR-BI-mediated [³H]cholesterol efflux to HDL in ldlA[mSR-BI] cells, with an IC₅₀ of 17.2 μM^[1].
BLT-3 enhances the binding of ¹²⁵I-HDL to SR-BI in ldlA[mSR-BI] cells by increasing binding affinity (decreasing K_d and Koff) without altering Bmax, with an IC₅₀ of 46.5 μM for its binding-enhancing effect^[1].